iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/33349876
Progress towards elimination of lymphatic filariasis in the Americas region - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 22;13(Suppl 1):S33-S38.
doi: 10.1093/inthealth/ihaa048.

Progress towards elimination of lymphatic filariasis in the Americas region

Gilberto Fontes  1 , Eliana Maria Mauricio da Rocha  1 , Ronaldo Guilherme Carvalho Scholte  2 , Rubén Santiago Nicholls  2
Affiliations

Progress towards elimination of lymphatic filariasis in the Americas region

Gilberto Fontes et al. Int Health. .

Abstract

In South and Central America, lymphatic filariasis (LF) is caused by Wuchereria bancrofti, which is transmitted by Culex quinquefasciatus, the only vector species in this region. Of the seven countries considered endemic for LF in the Americas in the last decade, Costa Rica, Suriname and Trinidad and Tobago were removed from the World Health Organization list in 2011. The remaining countries, Brazil, Dominican Republic, Guyana and Haiti, have achieved important progress in recent years. Brazil was the first country in the Americas to stop mass drug administration (MDA) and to establish post-MDA surveillance. Dominican Republic stopped MDA in all LF-endemic foci: La Ciénaga and Southwest passed the third Transmission Assessment Survey (TAS) and the Eastern focus passed TAS-1 in 2018. Haiti passed the TAS and interrupted transmission in >80% of endemic communes, achieving effective drug coverage. Guyana implemented effective coverage in MDAs in 2017 and 2018 and in 2019 scaled up the treatment for 100% of the geographical region, introducing ivermectin in the MDA in order to achieve LF elimination by the year 2026. The Americas region is on its way to eliminating LF transmission. However, efforts should be made to improve morbidity management to prevent disability of the already affected populations.

Keywords: Wuchereria bancrofti; Americas region; elimination program; lymphatic filariasis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Distribution of LF in countries and cities in the Americas, showing the current situation of LF elimination in each location and the status of MDA.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Orihel TC. Filariae. In: Beaver PC, Jung RC (). Animals agents and vectors of human disease, 5th ed Philadelphia: Lea & Febiger; 1985, p. 171–91.
    1. World Health Organization Lymphatic filariasis: a handbook of practical entomology. WHO/HTM/NTD/PCT/2013.10; Geneva: World Health Organization; 2013.
    1. Fontes G, Rocha EMM, Brito AC et al. . The microfilarial periodicity of Wuchereria bancrofti in northeastern Brazil. Ann Trop Med Parasitol. 2000;94(4):373–9. - PubMed
    1. World Health Organization Lymphatic filariasis: monitoring and epidemiological assessment of mass drug administration. A manual for national elimination programmes. WHO/HTM/NTD/PCT/2011.4 Geneva: World Health Organization; 2011.
    1. World Health Organization Fiftieth World Health Assembly, Geneva, 5–14 May 1997: resolutions and decisions, annexes. WHA50/1997/REC/1 Geneva: World Health Organization; 1997, p. 5–14.

Publication types